IL317823A - KRAS G12C inhibitor for cancer treatment - Google Patents
KRAS G12C inhibitor for cancer treatmentInfo
- Publication number
- IL317823A IL317823A IL317823A IL31782324A IL317823A IL 317823 A IL317823 A IL 317823A IL 317823 A IL317823 A IL 317823A IL 31782324 A IL31782324 A IL 31782324A IL 317823 A IL317823 A IL 317823A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- dose
- pharmaceutically acceptable
- cancer
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263357227P | 2022-06-30 | 2022-06-30 | |
| US202363486785P | 2023-02-24 | 2023-02-24 | |
| US202363496447P | 2023-04-17 | 2023-04-17 | |
| PCT/US2023/026554 WO2024006424A1 (en) | 2022-06-30 | 2023-06-29 | Kras g12c inhibitor for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317823A true IL317823A (en) | 2025-02-01 |
Family
ID=87468549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317823A IL317823A (en) | 2022-06-30 | 2023-06-29 | KRAS G12C inhibitor for cancer treatment |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240108618A1 (https=) |
| EP (1) | EP4547251A1 (https=) |
| JP (2) | JP7496917B2 (https=) |
| KR (1) | KR20250027777A (https=) |
| CN (1) | CN119907671A (https=) |
| CA (1) | CA3260047A1 (https=) |
| IL (1) | IL317823A (https=) |
| MA (1) | MA71325A (https=) |
| MX (1) | MX2025000105A (https=) |
| WO (1) | WO2024006424A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| PT3886991T (pt) * | 2019-12-11 | 2022-10-17 | Lilly Co Eli | Inibidores de kras g12c |
| WO2021222333A1 (en) * | 2020-04-30 | 2021-11-04 | Genentech, Inc. | Kras specific antibodies and uses thereof |
| WO2022031952A2 (en) * | 2020-08-07 | 2022-02-10 | City Of Hope | Treatments for cancers having kras mutations |
| CA3194067A1 (en) * | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4486345A1 (en) * | 2022-03-04 | 2025-01-08 | Eli Lilly and Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
-
2023
- 2023-06-29 EP EP23745331.1A patent/EP4547251A1/en active Pending
- 2023-06-29 CA CA3260047A patent/CA3260047A1/en active Pending
- 2023-06-29 WO PCT/US2023/026554 patent/WO2024006424A1/en not_active Ceased
- 2023-06-29 CN CN202380063188.1A patent/CN119907671A/zh active Pending
- 2023-06-29 US US18/344,134 patent/US20240108618A1/en active Pending
- 2023-06-29 MA MA71325A patent/MA71325A/fr unknown
- 2023-06-29 KR KR1020257002609A patent/KR20250027777A/ko active Pending
- 2023-06-29 IL IL317823A patent/IL317823A/en unknown
- 2023-06-30 JP JP2023108177A patent/JP7496917B2/ja active Active
-
2024
- 2024-05-28 JP JP2024086236A patent/JP2024112968A/ja active Pending
-
2025
- 2025-01-06 MX MX2025000105A patent/MX2025000105A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7496917B2 (ja) | 2024-06-07 |
| WO2024006424A1 (en) | 2024-01-04 |
| JP2024112968A (ja) | 2024-08-21 |
| JP2024007504A (ja) | 2024-01-18 |
| US20240108618A1 (en) | 2024-04-04 |
| CN119907671A (zh) | 2025-04-29 |
| MX2025000105A (es) | 2025-02-10 |
| EP4547251A1 (en) | 2025-05-07 |
| AU2023297941A1 (en) | 2025-01-16 |
| CA3260047A1 (en) | 2024-01-04 |
| KR20250027777A (ko) | 2025-02-27 |
| TW202421145A (zh) | 2024-06-01 |
| MA71325A (fr) | 2025-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL317823A (en) | KRAS G12C inhibitor for cancer treatment | |
| JP2024007504A5 (https=) | ||
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP6761852B2 (ja) | がん治療 | |
| IL290454B2 (en) | The compound dgd1202 for use in treating kras-associated cancers | |
| EP2501385B1 (en) | Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent | |
| WO2018083470A1 (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) | |
| CN110214023A (zh) | 基于5-氟尿嘧啶的化学疗法中多次团注施用[6r]-mthf | |
| WO2015134399A1 (en) | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer | |
| KR20090007635A (ko) | 철 킬레이터 및 항-신생물 약제를 포함하는 조합물 및 그의용도 | |
| CA3182018A1 (en) | Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor | |
| Wang et al. | Preclinical investigation of orally bioavailable, potent KRAS Multi inhibitor JAB-23425 | |
| EP2754441A2 (en) | Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives | |
| US20130338129A1 (en) | Method of treating refractory cancer | |
| WO2022165056A1 (en) | Treating cancer in patient with pten inactivating mutation | |
| US20220323443A1 (en) | Combination therapy for cancer treatment | |
| US20240173323A1 (en) | Combination therapy for cancer treatment | |
| JP2005527552A (ja) | 置換アクリロイルジスタマイシン誘導体および放射線療法を含む腫瘍に対する組合せ治療 | |
| Nair et al. | Repurposing Antifungal Drugs for Oral Cancer Treatment: Mechanistic Insights and Clinical Potential—A Narrative Review | |
| Shustov et al. | CHOP in combination with pralatrexate, a novel folate analogue metabolic inhibitor in patients with previously untreated peripheral t-cell lymphoma (PTCL): interim results of the phase 1 trial | |
| WO2025214358A1 (zh) | 用于治疗胰腺癌的药物及其用途 | |
| CN120420332A (zh) | 一种含mTOR抑制剂的组合物及其用途 | |
| HK40062087A (en) | Combination therapies for use in treating cancer | |
| Kabbinavar et al. | Results from a phase I trial of tivozanib (AV-951) combined with temsirolimus therapy in patients with renal cell carcinoma | |
| HK1154343B (en) | Therapeutic combination comprising a cdks inhibitor and an antineoplastic agent |